AR066478A1 - Derivados heterociclicos sustituidos y su uso farmaceutico y composiciones - Google Patents

Derivados heterociclicos sustituidos y su uso farmaceutico y composiciones

Info

Publication number
AR066478A1
AR066478A1 ARP080101937A ARP080101937A AR066478A1 AR 066478 A1 AR066478 A1 AR 066478A1 AR P080101937 A ARP080101937 A AR P080101937A AR P080101937 A ARP080101937 A AR P080101937A AR 066478 A1 AR066478 A1 AR 066478A1
Authority
AR
Argentina
Prior art keywords
alkyl
alkoxy
cycloalkyl
halogen
hydroxyl
Prior art date
Application number
ARP080101937A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR066478A1 publication Critical patent/AR066478A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Su preparacion y su uso como agentes antimicrobianos. Reivindicacion 1: Un compuesto de formula (1) o una sal o profármaco farmacéuticamente aceptable del mismo, o un hidrato o solvato de dicho compuesto, sal o profármaco, en la que: al menos unode X1, X2, X3, X4, X5 o X6 se selecciona de N o N-oxido y los restantes se seleccionan de N o CR1; cada R1 se selecciona independientemente de hidrogeno, halogeno, ciano, alquilo C1-6, alcoxi C1-6, haloalquilo C1-6, amino, hidroxilo, tiol oalquiltio C1-6; R2 se selecciona independientemente de hidrogeno, hidroxilo, halogeno, amino, alquilo C1-6, alquiltio C1-6, cicloalquilo C3-10, cicloalquil C3-10-alquilo C1-6, alquil C1-6-cicloalquilo C3-10, heterocicIoalquilo C2-9, heterociclo C2-9-alquilo C1-6, ariloxi C6-10, heterocicloxi C2-9, heterociclo C2-9-alcoxi C1-6, alcoxi C1-6, alcoxi C1-6-alquilo C1-6, fluorometilo, difluorometilo, trifluorometilo, fluorometoxi, difluorometoxi, trifluorometoxi, cicloalquiloxi C3-10, cicloalquiltioC3-10, aciloxi C1-6, ciano, nitro, en el que cualquiera de los grupos anteriormente mencionados (con la excepcion de hidrogeno, halogeno, ciano, hidroxilo y nitro) está opcionalmente sustituido con al menos un resto seleccionado de alquilo C1-6,cicloalquilo C3-10, alcoxi C1-6, cicloalcoxi C3-10, arilo C6-10, heteroarilo C5-9, carboxilo, alquiI C1-6oxicarbonilo, cicloalquil C3-10oxicarbonilo, acilo C1-6, halogeno, haloalquilo C1-6, haloalcoxi C1-6, alquilsulfonilo C1-6, aminocarbonilo,(alquil C1-6)aminocarbonilo, (alquil C1-6)2 aminocarbonilo, hidroxilo, heterocicloxi C2-9, ariloxi C6-10 o aciloxi C1-6; X7 se selecciona de O, NR5, CH2, -S-, SO o SO2 o -CR5H-; R4 se selecciona de hidrogeno, hidroxilo, alcoxi C1-6, fluoro, NH2,(alquil C1-6)NH-, (alquil C1-6)2N- o heterocicloalquilo C2-9, ciano o alquiltio C1-6; R5 se selecciona de hidrogeno; alquilo C1-6, alquil C1-6oxicarbonilo, aminocarbonilo, alquilsulfonilo C1-6 o alquil C1-6carbonilo; D es como en formula (2), C seselecciona de formula (3) en la ô ö indica un punto de union; Y1 es CR6 en la que R6 se selecciona de hidrogeno, hidroxilo, halogeno, alquilo C1-6 o R7 o Y1 es N y en los que uno de los átomos de carbono del anillo de cada uno de los gruposanulares C anteriores, junto con el grupo al que está unido, puede estar opcionalmente reemplazado por -C(O)-; cada R7 se selecciona independientemente de hidrogeno, halogeno, hidroxilo, alquilo C1-6, alcoxi C1-6, trifluorometilo, trifluorometoxi oamino, a condicion de que cuando Y1 es N y R7 es hidroxilo, alcoxi C1-6, amino, trifluorometoxi o halogeno, R7 no puede localizarse en un átomo adyacente a Y1; R8 se selecciona de arilo C6-10, ariloxi C6-10, aril C6-10-alquilo C1-6, aril C6-10-alcoxi C1-6, cicloalquilo C3-10, cicloalcoxi C3-10, cicloalquil C3-10-alcoxi C1-6, cicloalquil C3-10-alquilo C1-6, heteroaril C5-9-alquilo C1-6, heteroarilo C5-9, heteroaril C5-9-alcoxi C1-6, heteroariloxi C5-9, cicloalcoxi C3-10-alquilo C1-6,heterocicloalquilo C2-9, heterocicloxi C2-9, heterociclo C2-9-alquilo C1-6, heterociclo C2-9-alcoxi C1-6, en los que cualquiera de los grupos anteriormente mencionados puede estar opcionalmente sustituido con 1 a 4 restos seleccionados cada unoindependientemente de halogeno, alquilo C1-6, aIcoxi C1-6, alcoxi C1-6-alquilo C1-6, carboxilo, haloalquilo C1-6, haloalcoxi C1-6, tiol, alquiltio C1-6, hidroxilo, nitro, ciano amino, mono- o dialquilamino C1-6, arilo C6-10, heteroarilo C5-9,alcoxiC1-6carbonilo, alcoxi C1-6-carbonilalquilo C1-6, cicloalquilo C3-10, alquilC1-6carbonilo, alquilsulfinilo C1-6, alquilsulfonilo C1-6, aminocarbonilo, mono- y dialquil C1-6aminocarbonilo, aciltio C1-6 o aciloxi C1-6; o R7 y R8, junto con losátomos a los que están unidos, forman un sistema anular saturado o insaturado o aromático de 3 a 8 miembros que puede ser monociclico o bicíclico, en el que dicho sistema anular puede contener opcionalmente al menos un heteroátomo seleccionado denitrogeno, oxigeno o azufre, y en el que dicho sistema anular puede estar opcionalmente sustituido con 1 a 4 restos seleccionados cada uno independientemente de hidroxilo, halogeno, ciano, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, cicloalquilo C3-10, cicloalcoxi C3-10, formilo, acilo C1-6, alcoxi C1-6-carbonilo, heterocicloalquilo C2-9, arilo C6-10 o heteroarilo C5-C9; R9 se selecciona de carboxilo, alcoxi C1-6-carbonilo, aminocarbonilo, alquilC1-6aminocarbonilo, aIquil C1-6sulfonilaminocarbonilo, hidroxilo, hidroximetilo o tetrazol; R10 se selecciona de hidrogeno, halogeno, hidroxilo, alquilo C1-6 o haloalquilo C1-6; n es 0,1, 2 o 3; m es 0, 1, 2 o 3; p es 0 o 1; y q es 0, 1o 2.
ARP080101937A 2007-05-09 2008-05-07 Derivados heterociclicos sustituidos y su uso farmaceutico y composiciones AR066478A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91690607P 2007-05-09 2007-05-09

Publications (1)

Publication Number Publication Date
AR066478A1 true AR066478A1 (es) 2009-08-19

Family

ID=39865577

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101937A AR066478A1 (es) 2007-05-09 2008-05-07 Derivados heterociclicos sustituidos y su uso farmaceutico y composiciones

Country Status (17)

Country Link
US (3) US20080280879A1 (es)
EP (2) EP2155716A2 (es)
JP (1) JP2010526130A (es)
KR (2) KR20090130347A (es)
CN (1) CN101679357A (es)
AR (1) AR066478A1 (es)
AU (1) AU2008249745B2 (es)
CA (1) CA2685888A1 (es)
CL (1) CL2008001367A1 (es)
IL (1) IL201830A0 (es)
MX (1) MX2009012117A (es)
PA (1) PA8779801A1 (es)
PE (1) PE20090240A1 (es)
TW (1) TW200902518A (es)
UY (1) UY31071A1 (es)
WO (1) WO2008139288A2 (es)
ZA (1) ZA200907761B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2767478A1 (en) * 2009-07-11 2011-01-20 Bayer Pharma Aktiengesellschaft Radiolabelling method using cycloalkyl groups
MA41169A (fr) 2014-12-17 2017-10-24 Acraf Composés antibactériens à large spectre d'activité
US10633366B2 (en) 2016-06-08 2020-04-28 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Antibacterial compounds
JP6755775B2 (ja) * 2016-11-04 2020-09-16 富士アミドケミカル株式会社 ４−フルオロイソキノリンの製法
CN108627579B (zh) * 2017-03-24 2020-12-01 上海安谱实验科技股份有限公司 Pbt制品中多环芳烃的提取方法
CN112236415B (zh) * 2017-12-26 2023-11-14 赛特凯恩蒂克公司 氨基嘧啶的制备方法和其中间体
US11866431B2 (en) 2018-11-09 2024-01-09 Vivace Therapeutics, Inc. Bicyclic compounds
TWI849107B (zh) 2019-04-16 2024-07-21 美商維瓦斯治療公司 雙環化合物
CN111848423B (zh) * 2019-04-30 2022-10-14 尚科生物医药（上海）有限公司 3-氧代环丁基氨基甲酸叔丁酯的制备方法
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
WO2022006457A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022006456A1 (en) 2020-07-02 2022-01-06 Incyte Corporation Tricyclic pyridone compounds as jak2 v617f inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
WO2022140231A1 (en) 2020-12-21 2022-06-30 Incyte Corporation Deazaguaine compounds as jak2 v617f inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
WO2023078252A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
US12084430B2 (en) 2022-03-17 2024-09-10 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4096146A (en) * 1968-07-02 1978-06-20 Hoffmann-La Roche Inc. 4-[5(R)-Alkyl(or alkenyl)-4(S)-quinuclidin-2(S) or 2(R)-ylcarbonyl]-quinolines, antipodes or racemates thereof and processes for their preparation
US3869461A (en) * 1968-07-02 1975-03-04 Hoffmann La Roche Intermediates for quinine, quinidine and derivatives thereof
US3828048A (en) * 1970-10-14 1974-08-06 Res Et D Applic Scient Sogeras Alkylsulfonic derivatives of quinine alkaloids
US4002757A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated N-(1-substituted-3-pyrrolidinyl)-4-quinolinecarboxamides
PT66682B (pt) * 1976-06-18 1978-11-15 Ind Biolog Francaise /(quinolyl-4)-propyl-1/-4 piperidines leur preparation et leur utilisation comme medicaments /(quinolyl-4)-propyl/-4 piperidines leur preparation et leur utilisation comme medicaments
NL7908031A (nl) * 1979-11-01 1981-06-01 Acf Chemiefarma Nv Nieuwe chinolinederivaten en farmaceutische preparaten die een dergelijke verbinding bevatten, alsmede werk- wijze voor het bereiden van deze verbindingen.
FR2471981A1 (fr) * 1979-12-21 1981-06-26 Pharmindustrie Nouveaux derives de la (piperidyl-4)-2 (quinolyl-4)-1 ethanone, produits intermediaires et procedes pour leur preparation, et leur utilisation comme medicaments
FR2495470A1 (fr) * 1980-12-05 1982-06-11 Pharmindustrie Nouveaux medicaments a base de derives de (quinolyl-4)-1 (piperidyl-4)-2 ethanol ou (quinolyl-4)-1 (piperidyl-4)-3 propanol
US4757079A (en) * 1986-06-24 1988-07-12 Dynamac Corporaton Anti-hypertensive piperidine compounds
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5260331A (en) * 1989-01-02 1993-11-09 John Wyeth & Brother Limited Composition for treating depression with (S- or O-heteroaryl)alkyl amines
FR2642069B1 (fr) * 1989-01-20 1991-04-12 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1991015205A1 (fr) * 1990-04-06 1991-10-17 Eisai Co., Ltd. Preparation buccale solide contenant un compose de catechol
EP0533882B1 (en) * 1991-04-03 2001-02-07 Korea Research Institute Of Chemical Technology 2-quinolinone derivatives, methods for preparing the same and fungicides and insecticides including them
CA2075154A1 (en) * 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
GB9216297D0 (en) * 1991-08-15 1992-09-16 Ici Plc Therapeutic agents
FR2695126B1 (fr) * 1992-08-27 1994-11-10 Sanofi Elf Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant.
DE4321030A1 (de) * 1993-06-24 1995-01-05 Bayer Ag 4-bicyclisch substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel
GB9318691D0 (en) * 1993-09-09 1993-10-27 Merck Sharp & Dohme Therapeutic agents
US5512581A (en) * 1994-07-18 1996-04-30 Abbott Laboratories Iminoxycarboxylates and derivatives as inhibitors of leukotriene biosynthesis
US5721103A (en) * 1994-12-30 1998-02-24 Ligand Pharmaceuticals Incorporated Trienoic retinoid compounds and methods
US5741789A (en) * 1995-01-17 1998-04-21 Eli Lilly And Company Compounds having effects on serotonin-related systems
WO1997014681A1 (en) * 1995-10-16 1997-04-24 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic compounds as h+-atpases
DE19613329A1 (de) * 1996-04-03 1997-10-09 Hoechst Schering Agrevo Gmbh Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
BR9709105A (pt) * 1996-05-20 1999-08-03 Darwin Discovery Ltd Sulfonamidas de quinolina como inibidoras de tnf e como inobidoras de pde-iv
WO1997044037A1 (en) * 1996-05-20 1997-11-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO1997044339A1 (en) * 1996-05-20 1997-11-27 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6147088A (en) * 1996-05-20 2000-11-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
ATE300521T1 (de) * 1996-09-25 2005-08-15 Astrazeneca Ab Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
US6274598B1 (en) * 1996-10-28 2001-08-14 The United States Of America As Represented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
US6767991B1 (en) * 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
EP1051413B1 (en) 1998-01-26 2003-06-04 SmithKline Beecham plc Quinoline derivatives as antibacterials
US6172087B1 (en) * 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
US6303627B1 (en) * 1998-06-19 2001-10-16 Eli Lilly And Company Inhibitors of serotonin reuptake
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
GB9819384D0 (en) * 1998-09-04 1998-10-28 Cerebrus Ltd Chemical compounds II
GB9822450D0 (en) * 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
GB9822440D0 (en) * 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
WO2000043383A1 (en) * 1999-01-20 2000-07-27 Smithkline Beecham P.L.C. Piperidinylquinolines as protein tyrosine kinase inhibitors
GB9910579D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910580D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
FR2798656B1 (fr) * 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
US6403610B1 (en) * 1999-09-17 2002-06-11 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation and the compositions which comprise them
US6794389B2 (en) * 2000-03-31 2004-09-21 Nippon Shinyaku Co., Ltd. Quinazoline derivatives and drugs
US6803369B1 (en) * 2000-07-25 2004-10-12 Smithkline Beecham Corporation Compounds and methods for the treatment of neoplastic disease
PT1650203E (pt) * 2000-09-11 2008-05-13 Novartis Vaccines & Diagnostic Processo de preparação de derivados de benzimidazol-2-ilquinolinona
US6603005B2 (en) * 2000-11-15 2003-08-05 Aventis Pharma S.A. Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
US6650463B2 (en) * 2001-03-13 2003-11-18 Seiko Epson Corporation Electrophoretic display device
US6602884B2 (en) * 2001-03-13 2003-08-05 Aventis Pharma S.A. Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
WO2003060852A2 (en) * 2002-01-15 2003-07-24 Michigan State University Catalytic osmium-assisted oxidative cleavage of olefins
FR2842807A1 (fr) * 2002-07-23 2004-01-30 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, procede et intermediaires de preparation et compositions les renfermant
DE10316081A1 (de) * 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
US7348434B2 (en) 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
BRPI0617376A2 (pt) * 2005-10-13 2011-07-26 Morphochem Ag derivados de 5-quinolina tendo uma atividade antibacteriana

Also Published As

Publication number Publication date
PE20090240A1 (es) 2009-03-19
US20110092480A1 (en) 2011-04-21
US20080280879A1 (en) 2008-11-13
KR20120011093A (ko) 2012-02-06
CN101679357A (zh) 2010-03-24
IL201830A0 (en) 2010-06-16
ZA200907761B (en) 2010-08-25
MX2009012117A (es) 2009-11-23
WO2008139288A3 (en) 2009-03-26
CL2008001367A1 (es) 2008-11-07
TW200902518A (en) 2009-01-16
WO2008139288A2 (en) 2008-11-20
KR20090130347A (ko) 2009-12-22
JP2010526130A (ja) 2010-07-29
EP2481735A1 (en) 2012-08-01
EP2155716A2 (en) 2010-02-24
UY31071A1 (es) 2009-01-05
PA8779801A1 (es) 2009-01-23
US20120065188A1 (en) 2012-03-15
AU2008249745A1 (en) 2008-11-20
AU2008249745B2 (en) 2012-01-12
CA2685888A1 (en) 2008-11-20

Similar Documents

Publication Publication Date Title
AR066478A1 (es) Derivados heterociclicos sustituidos y su uso farmaceutico y composiciones
AR118123A2 (es) Derivados de isoxazolidina, proceso para preparar dichos compuestos, composición farmacéutica y combinación
AR060562A1 (es) Compuestos heterociclicos como antagonistas del receptor il-8. procesos de obtencion y composiciones farmaceuticas.
AR060605A1 (es) Derivados de diazepano como antagonistas del receptor ccr2
AR060401A1 (es) Derivados de cromen-2-ona
AR079231A1 (es) Derivados de imidazoquinolina
AR059458A1 (es) Arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparacion y su uso como medicamentos
AR047890A1 (es) Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3
CO6170061A1 (es) Compuestos de pirandiona, tiopirandiona y ciclohexantriona utiles como herbicidas, procesos para su preparacion, intermediarios utiles en su preparacion, metodos para controlar hierbas y malezas en cultivos de plantas utiles utilizando dichos herbici
AR063684A1 (es) Derivados de 4, 4´-bifenildiilbis(1h-imidazol-5, 2-diil) como inhibidores del virus de la hepatitis c, composicion que los comprende y su uso para tratar una infeccion con vhc.
AR088449A1 (es) Benzilindazoles sustituidos
PE20141935A1 (es) Compuestos de dioxido de iminotiadiazina como inhibidores de bace, composiciones, y su uso
PE20130155A1 (es) Derivados de ariletinilo
ES2529233T3 (es) Compuestos tetrazol como bloqueadores de canales de calcio
ECSP109932A (es) Compuestos de biciclolactama sustituida
AR064635A1 (es) Derivados de benzotiazolona
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR061923A1 (es) Compuestos derivados de benzofuran-piperidina
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
AR072052A1 (es) Derivados de indano como reguladores del receptor ampa
AR054789A1 (es) Antagonistas del receptor 1 de triazolopiridina canabinoide
AR066492A1 (es) Derivados de imidazoquinolina, proceso para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de enfermedades virales, bacterianas, alergicas y distintos tipos de canceres.
AR070463A1 (es) Compuestos de amina y eter que modulan el receptor cb2
AR065280A1 (es) Agentes antiparasitarios
AR061651A1 (es) Analogos de piridina ii

Legal Events

Date Code Title Description
FA Abandonment or withdrawal